Lixisenatide: Phase III data

Top-line data from the double-blind, Asian Phase III GETGOAL-L-ASIA trial in 311 patients inadequately controlled with basal insulin showed that once-daily lixisenatide as an add-on to basal insulin with or without sulfonylurea met the primary endpoint of significantly reducing HbA1c from baseline to week 24 vs. placebo (0.88%, p<0.0001). The percent value for placebo was not disclosed. No specific safety concerns were identified. ...